Unveiling the mechanisms of immune evasion in pancreatic cancer: may it be a systemic inflammation responsible for dismal survival?
- 34 Downloads
Pancreatic cancer (PC) is one of the most aggressive malignancies with no effective treatment if diagnosed in advanced stage. Systemic inflammation is a recognized characteristic of cancer progression, and we believe that the understanding of the influence of inflammatory parameters may contribute to therapeutic improvement in PC. Here, we validated the Eosinophil/Lymphocyte Ratio (ELR) together with the Neutrophil/Lymphocyte Ratio (NLR) and their components, as prognostic factors in PC patients treated with chemoradiation.
A total of 66 consecutive patients (p) diagnosed with PC stage I–III and treated with External Beam Radiotherapy + chemotherapy ± surgery (28p) in our institution from 2007 to 2018 were retrospectively evaluated. The impact of pre-treatment ELR ≥ 0.04, NLR ≥ 1.9, neutrophilia (≥ 7.0 × 10(9)/l), eosinophilia (≥ 0.5 × 10(9)/l) and lymphopenia (< 1.0 × 10(9)/l) on Overall Survival (OS) and Time-to-Progression (TTP) was evaluated both in the entire cohort and separately according to surgical status.
Higher ELR was associated with longer OS and TTP, both in surgically treated and not operable patients. On univariate analysis, elevated ELR was associated with better OS (HR = 0.3, 95% IC 0.13–0.65, p = 0.003), contrarily to neutrophilia (HR = 2.7, 95% IC 1.2–6.5, p = 0.026) and age > 50 years (HR = 2.6, 95% IC 1.03–6.6, p = 0.044), while NLR, lymphopenia and Ca-19.9 were not significant. On multivariate regression, independent prognosticators for OS were: ELR, age and neutrophilia; while for TTP: ELR, neutrophilia, eosinophilia and lymphopenia.
The host’s immune response influences survival outcomes of PC patients and may be of interest for future research.
KeywordsPancreatic cancer Systemic inflammation Neutrophil/lymphocyte ratio Eosinophil/lymphocytes ratio Eosinophils Neutrophils
This article was principally written by KH, with review contributions from CC. Both authors have read and approved the final version of the manuscript.
There was no specific funding for this study.
Compliance with ethical standards
The datasets used and/or analysed during the current study are available on reasonable request.
Conflict of interest
No potential conflict of interest to disclose.
Our study was approved by the Ethical Committee of the Hospital Clinic de Barcelona.
All patients included in the study signed the informed consent for treatment, data processing and publication.
- 1.National Cancer Institute: SEER Stat Fact Sheets: Pancreatic Cancer. http://seer.cancer.gov/statfacts/html/corp.html. Accessed 28 Dec 2018.
- 2.European Cancer Information System: Data Explorer https://ecis.jrc.ec.europa.eu/explorer.php Accessed 9 Jan 2019.
- 4.Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015;26(5):56–68. https://doi.org/10.1093/annonc/mdv295 (e-update—cancer of the pancreas treatment recommendations. Published: 15 March 2019. Authors: ESMO Guidelines Committee).CrossRefGoogle Scholar
- 8.Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C, Stojakovic T, Samonigg H, Hoefler G, Pichler M. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109:416–21.CrossRefGoogle Scholar
- 9.Asaoka T, Miyamoto A, Maeda S, Tsujie M, Hama N, Yamamoto K, Miyake M, Haraguchi N, Nishikawa K, Hirao M, Ikeda M, Sekimoto M, Nakamori S. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. Pancreatology. 2016;16(3):434–40. https://doi.org/10.1016/j.pan.2015.10.006.CrossRefGoogle Scholar
- 10.Asari S, Matsumoto I, Toyama H, Shinzeki M, Goto T, Ishida J, Ajiki T, Fukumoto T, Ku Y. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios. Surg Today. 2016;46:583–92.CrossRefGoogle Scholar
- 12.Sierzega M, Lenart M, Rutkowska M, Surman M, Mytar B, Mataja A, Siedlar M, Kulig J. Preoperative neutrophil-lymphocyte and lymphocyte-monocyte ratios reflect immune cell population rearrangement in resectable pancreatic cancer. Ann Surg Oncol. 2017;24:808–15. https://doi.org/10.1245/s10434-016-5634-0.CrossRefGoogle Scholar
- 16.Giakoustidis A, Neofytou K, Costa Neves M, Giakoustidis D, Louri E, Cunningham D, Mudan S. Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg. 2018;22(3):197–207. https://doi.org/10.14701/ahbps.2018.22.3.197.CrossRefGoogle Scholar
- 25.Holub K, Biete A (2018) Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients. Clin Transl Oncol. https://doi.org/10.1007/s12094-018-1991-4.